Law360 (November 15, 2007, 12:00 AM EST) -- The Food and Drug Administration released new policy guidelines for its advisory committees Thursday on the heels of concerns about potential conflicts of interest posed by members' ties to the industries they regulate.
Some of those guidelines contained advice for how the committees could best generate discussion among members. Committee members should be given thorough, helpful briefing materials before meetings, and at meetings all members' views should be solicited before voting has begun in order to guarantee a consistent understanding of issues presented, the FDA said....
FDA Brushes Up On Committee Transparency
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
